Xiaojian Yan - The First Affiliated Hospital, Wenzhou Medical University

基本信息

浏览量：14

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 57 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Primary Low-Grade Vaginal Extrauterine Endometrial Stromal Sarcoma: A Case Report

Portia Cobbinah, Lanting Xiang, Francis Oklah,Xiaojian Yan, Lijiao Hou

Reproductive Sciencesno. 5 (2025): 1699-1704

引用0浏览0WOS引用

Survival Analysis of Recurrent Ovarian Cancer under Different PARP Inhibitor Treatment Patterns: a Single-Center Retrospective Study

Jingtian Shen, Xi Wang, Olivier Mpano,Ying Wang,Yihan Shan, Xinning Lou,Piaopiao Ye,Xiaojian Yan

FRONTIERS IN ONCOLOGY (2025)

引用0浏览0WOS引用

Corrigendum to ‘efficacy and Safety of Paclitaxel Liposome Versus Paclitaxel in Combination with Carboplatin in the First-Line Chemotherapy for Ovarian Cancer: a Multicenter, Open-Label, Non-Inferiority, Randomized Controlled Trial’ [journal of the National Cancer Center 4 (2024) 135–141]

Rong Li,Hongping Zhang,Qingshui Li,Guangwen Yuan,Yanjie Zhou,Rutie Yin, He Wang, Chunyan Wang, Yi Huang,Wei Wang,Xiaojian Yan,Lingying Wu,Qi Zhou

Journal of the National Cancer Center (2025)

引用0浏览0WOS引用

The Significance of Lymph Node Dissection in Patients with Early Epithelial Ovarian Cancer

Ruru Bao, Mpano Olivier,Junmiao Xiang,Piaopiao Ye,Xiaojian Yan

Annali Italiani di Chirurgia（2024）

引用0浏览0WOS引用

Cadonilimab Plus Platinum-Based Chemotherapy with or Without Bevacizumab As First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (COMPASSION-16): a Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial in China

LANCET（2024）

引用2浏览0WOS引用

MUL1 Identified As Mitochondria-Linked Biomarker Promoting Cisplatin Resistance in OC Cells

Lixiao Liu,Chengyang Zou, Jingtian Shen, Rong Huang,Fubin Zhang,Yongming Du,Xishao Luo, Aiwu Yang,Jinsan Zhang,Yutao Guan,Xiaojian Yan

Gene（2024）

引用0浏览0WOS引用

Efficacy and Safety of Paclitaxel Liposome Versus Paclitaxel in Combination with Carboplatin in the First-Line Chemotherapy for Ovarian Cancer: A Multicenter, Open-Label, Non-Inferiority, Randomized Controlled Trial

Rong Li,Hongping Zhang,Qingshui Li,Guangwen Yuan,Yanjie Zhou,Rutie Yin, He Wang,Chunyan Wang,Yi Huang,Wei Wang,Xiaojian Yan,Lingying Wu,Qi Zhou

Journal of the National Cancer Centerno. 2 (2024): 135-141

引用0浏览0WOS引用

LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer

Pedro T. Ramirez,Kristy P. Robledo,Michael Frumovitz,Rene Pareja,Reitan Ribeiro,Aldo Lopez,Xiaojian Yan,David Isla,Renato Moretti,Marcus Q. Bernardini,Val Gebski,Rebecca Asher,Vanessa Behan,Robert L. Coleman,Andreas Obermair

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用7浏览0WOS引用

Lipid Prodrug Nanoassemblies Via Dynamic Covalent Boronates

Yuxun Ding,Xiaowen Hu,Yinzi Piao, Rong Huang,Lingping Xie,Xiaojian Yan,Hui Sun,Yuanfeng Li,Linqi Shi,Yong Liu

ACS Nanono. 7 (2023): 6601-6614

引用32浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn